Abstract:Ground breaking advances in medicine, driven in part by major technologic developments in molecular biology have led us to a new model for cancer care that has been termed personalized, or precision medicine. Precision medicine is a model for making medical decisions that employs an innovative clinical approach and advanced tumor testing methods that are tailored to understanding an individual patient's tumor biology and the molecular drivers of their disease. This medical model includes a combination of diagnostic testing and specific treatment options that can be offered to patients at presentation and in theory throughout the course of their disease as new mutations arise with the development of disease recurrence. Although the precision medicine model offers incredible potential to transform cancer care, these advances are only meaningful when they reach the correct patients. The evolving paradigm of precision medicine is changing the practice of pathology, and the pathology community needs to be mindful of these changes because every tissue specimen represents a patient's life, and those patients are depending on the pathology community to handle their tissue correctly. The diagnostic tests performed in the pathology laboratory for precision medicine are increasingly complex, and pathologists along with the entire laboratory and clinical communities need to take steps to ensure that the right diagnosis is given to the right patient to inform the right treatment options, at the right time, along every step of the continuum of care for cancer patients. While hormone receptors and human epidermal growth factor receptor 2 (HER2) overexpression and/or amplification have been the mainstay for risk-stratification, and treatment decision making in breast cancer since the early 2000's, the seminal work on gene expression by Perou and colleagues in the early 2000's opened the door for molecular testing in the prognostic and predictive assessment of breast cancer. Molecular testing is now part of the standard of care in the precision medicine model for breast cancer care. In this article, the reader will gain a better understanding of how the lack of standardization of pre-analytic factors has the potential to negatively impact the quality of the tissue specimen for downstream biomarker and molecular testing, which ultimately can negatively affect patient care. The reader will also gain insight into the current climate surrounding molecular testing in breast cancer.

Treatment Seeking Behavior and Health Care Expenditure Incurred for Hypertension among elderly in Urban Slums of Belgaum City

Current and emerging biomarkers in breast cancer: prognosis and prediction

Emerging Biomarkers and New Understanding of Traditional Markers in Personalized Therapy for Breast Cancer

Biomarkers for the clinical management of breast cancer: International perspective

Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update

Prognostic and predictive biomarkers in breast cancer: Past, present and future

Validated biomarkers: The key to precision treatment in patients with breast cancer

Biomarkers in breast cancer 2024: an updated consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology

The role of targeted therapy and biomarkers in breast cancer treatment

Biomarkers for personalized oncology: recent advances and future challenges

Predictive markers of endocrine response in breast cancer

Optimized biomarker evaluation and molecular testing in the era of breast cancer precision medicine

Evaluation of techniques for chemical debridement of colonic mucosa.

Current and emerging breast cancer biomarkers

Biomarkers for breast cancer immunotherapy: PD-L1, TILs, and beyond

Prognostic and Predictive Markers for Treatment Decisions in Early Breast Cancer

Accurate prediction of response to endocrine therapy in breast cancer patients: current and future biomarkers

Breast cancer immunotherapy and personalized medicine

Biomarkers in Breast Cancer: An Old Story with a New End

Updates in Systemic Treatment of Hormone Receptor-Positive Early-Stage Breast Cancer

Innovative Therapeutic Approaches for Patients with HER2-Positive Breast Cancer